ABVX vs CTXR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and CTXR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and CTXR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and, more recently, commercializes specialty products. Its lead asset is LYMPHIR (denileukin diftitox-cxdl), a targeted immunotherapy approved by the FDA for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have had at least one prior systemic therapy. LYMPHIR is being commercialized largely through Citius Oncology (Nasdaq: CTOR), a separately listed subsidiary in which Citius Pharmaceuticals holds a majority stake (a stake that has declined over time as the subsidiary raised financing). Beyond LYMPHIR, the company's pipeline includes Mino-Lok, an antibiotic catheter-lock solution that met the primary and secondary endpoints of its Phase 3 trial, and CITI-002 (Halo-Lido), a topical treatment for hemorrhoids.

Full CTXR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• CTXR drivers: LYMPHIR commercial ramp; Pipeline optionality (Mino-Lok and Halo-Lido).

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For CTXR, the dominant risks are financial.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; CTXR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and CTXR guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

CTXR. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a small, early-commercial biopharma like Citius, standard valuation multiples such as P/E are not useful because the company is not consistently profitable. What matters far more is cash runway, the pace of the LYMPHIR revenue ramp, pipeline progress, and how much shareholder dilution future financing requires. The reverse split and low cash balance are central to the risk picture and should be weighed carefully alongside any commercial optimism.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; CTXR shows profitability Not consistently profitable; an early-commercial biopharma, so no meaningful P/E, cash position ~$4.6 million reported as of March 31, 2026 (approximate; a key constraint), lymphir revenue A few million dollars since the late-2025 launch (about $5.6 million net for the first half of fiscal 2026, at roughly 80% gross margins; approximate), share structure 1-for-25 reverse stock split effected November 2024 to maintain Nasdaq listing; ongoing dilution from financings.

ABVX and CTXR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and CTXR exposure against your real portfolio. It is not an investment adviser.